Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future.

Autor: Santos, João Paulo Margiotti dos, Maio, Mariana Canevari de, Lemes, Monike Alves, Laurindo, Lucas Fornari, Haber, Jesselina Francisco dos Santos, Bechara, Marcelo Dib, Prado Jr., Pedro Sidnei do, Rauen, Eduardo Costa, Costa, Fernando, Pereira, Barbara Cristina de Abreu, Flato, Uri Adrian Prync, Goulart, Ricardo de Alvares, Chagas, Eduardo Federighi Baisi, Barbalho, Sandra Maria
Předmět:
Zdroj: International Journal of Molecular Sciences; Jan2022, Vol. 23 Issue 1, p498, 1p
Abstrakt: Non-alcoholic steatohepatitis (NASH) is characterized by steatosis, lobular inflammation, and enlargement of the diameter of hepatocytes (ballooning hepatocytes), with or without fibrosis. It affects 20% of patients with non-alcoholic fatty liver disease (NAFLD). Due to liver dysfunction and the numerous metabolic changes that commonly accompany the condition (obesity, insulin resistance, type 2 diabetes, and metabolic syndrome), the secretion of organokines is modified, which may contribute to the pathogenesis or progression of the disease. In this sense, this study aimed to perform a review of the role of organokines in NASH. Thus, by combining descriptors such as NASH, organokines, oxidative stress, inflammation, insulin resistance, and dyslipidemia, a search was carried out in the EMBASE, MEDLINE-PubMed, and Cochrane databases of articles published in the last ten years. Insulin resistance, inflammation and mitochondrial dysfunction, fructose, and intestinal microbiota were factors identified as participating in the genesis and progression of NASH. Changes in the pattern of organokines secretion (adipokines, myokines, hepatokines, and osteokines) directly or indirectly contribute to aggravating the condition or compromise homeostasis. Thus, further studies involving skeletal muscle, adipose, bone, and liver tissue as endocrine organs are essential to better understand the modulation of organokines involved in the pathogenesis of NASH to advance in the treatment of this disease. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Nepřihlášeným uživatelům se plný text nezobrazuje